Intraperitoneal immunotherapy of cancer: A review of options for treatment

Claasen, Hedda H. van Ravenswaay; Eggermont, Alexander M.M.

doi:10.1007/978-1-4613-1247-5_2

Cited by 2 publications

(3 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mps perform a multitude of functions essential for tissue remodeling, in£ammation and immunity by secreting cytokines, growth factors and prostaglandins [15]. The majority of malignant tumors contain Mps as a major component of the host leukocytic in¢ltrate [4]. These tumor-associated Mps are recruited into the tumor mass from the circulation by the action of di¡erent chemotactic factors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Arginine metabolic pathways involved in the modulation of tumor‐induced angiogenesis by macrophages

et al. 2002

View full text Add to dashboard Cite

Neovascularization, an essential step for tumor progression and metastasis development, can be modulated by the presence of macrophages (Mps) in the tumor microenvironment. The ability of Mps to regulate the angiogenicity of the LMM3 tumor cell line was studied. Peritoneal Mps from LMM3 tumor-bearing mice (TMps) potentiate in vivo LMM3 angiogenicity. These results were con¢rmed by CD31 immunoblotting assays. The activity of TMps depended on nitric oxide synthase (NOS) and arginase (A) activity. By immunoblotting we evidenced that AI and AII isoforms were up-regulated in TMps while the inducible and neuronal NOS isoforms were highly expressed in normal Mps. TMps might positively modulate tumor growth by stimulating angiogenic cascade mainly through polyamine synthesis. ß 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Malignant tumors contain macrophages (Mps) as a major component of the host leukocytic in¢ltrate and the role of Mps in tumor progression have given o¡ contradictory evidence [4]. It has been recognized that Mps can act either as negative regulators by achieving tumor cytotoxicity, or as positive regulators by promoting tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Arginine metabolic pathways involved in the modulation of tumor‐induced angiogenesis by macrophages

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Other treatment modalities are now the subject of phase III studies. So far, results of clinical studies on intraperitoneal immunotherapy [27,28], radioimmunotherapy [27,28] and photodynamic therapy [29±33] have not demonstrated signi®cant therapeutic bene®t, when compared with systemic chemotherapy. In this paper we will discuss the available data on intraperitoneal chemotherapy in the management of colorectal cancer.…”

Section: Regional Treatmentmentioning

confidence: 99%

Intraperitoneal chemotherapy for colorectal cancer

Bree

Witkamp

Zoetmulder

2001

Journal of Surgical Oncology

View full text Add to dashboard Cite

The peritoneal surface remains an important failure site for patients with colorectal cancer. Peritoneal metastases of colorectal cancer are at present considered equal to distant metastatic disease. Consequently, peritoneal carcinomatosis is treated with systemic chemotherapy and surgery only to palliate complications such as obstruction. Despite the development of new chemotherapeutic agents and combinations, the results remain disappointing with a limited impact on survival. Colorectal carcinoma cells are relatively resistant to chemotherapy. Intraperitoneal chemotherapy seems to be an attractive approach in the treatment of high-risk colorectal cancer and peritoneal carcinomatosis from colorectal origin providing high local drug concentration with limited systemic side effects. Adjuvant early postoperative intraperitoneal chemotherapy is worthwhile for consideration as treatment option after resection of high-risk colorectal cancer. In the treatment of peritoneal carcinomatosis postoperative intraperitoneal chemotherapy leads to inadequate exposure of the peritoneal surface. Only an intraoperative intraperitoneal chemotherapy performed with direct cytotoxic drugs such as MMC and cisplatin overcome this problem. The limited drug penetration in tissue implies the need for extensive cytoreductive surgery. The results of phase II studies suggest that an increased median survival can be achieved with this approach. The natural history of this disease and the heterogeneity of the patients are such that only a randomized trial design will adequately answer the question whether regional treatment of patients with peritoneal dissemination of colorectal cancer actually prolongs survival. The results of such a study are to be expected in approximately 2 years time.

show abstract

Intraperitoneal immunotherapy of cancer: A review of options for treatment

Cited by 2 publications

References 122 publications

Arginine metabolic pathways involved in the modulation of tumor‐induced angiogenesis by macrophages

Arginine metabolic pathways involved in the modulation of tumor‐induced angiogenesis by macrophages

Intraperitoneal chemotherapy for colorectal cancer

Contact Info

Product

Resources

About